Classification of COPD: fostering prevention and precision medicine in the Lancet Commission on COPD
- PMID: 36075257
- DOI: 10.1016/S0140-6736(22)01660-9
Classification of COPD: fostering prevention and precision medicine in the Lancet Commission on COPD
Conflict of interest statement
GGB has received payments from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi for advisory boards and lectures on asthma, COPD, interstitial lung disease, and chronic cough. MH declares payments for advisory boards or lectures on asthma or pulmonary hypertension from Acceleron, Aerovate, Altavant, AOP Orphan, AstraZeneca, Bayer, Chiesi, Ferrer, GlaxoSmithKline, Janssen, Merck, MorphogenIX, Novartis, Sanofi, Shou Ti, and United Therapeutics, and grants to his institution from Acceleron, AOP Orphan, Janssen, Merck, and Shou Ti.
Comment on
-
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.Lancet. 2022 Sep 17;400(10356):921-972. doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5. Lancet. 2022. PMID: 36075255 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical